Klox Technologies and LEO Pharma set up company for BioPhotonic in dermatology
(Thomson Reuters ONE) -
LAVAL, Quebec and BALLERUP, Denmark, March 06, 2017 (GLOBE NEWSWIRE) -- Klox
Technologies Inc. ('Klox') and LEO Pharma A/S ('LEO Pharma') to establish a
jointly owned company to further develop and commercialize Klox's BioPhotonic
technology in dermatology including Kleresca® for acne and Kleresca® for skin
rejuvenation. Both companies bring in their contributions from their existing
collaboration which started in 2014.
The Kleresca® treatment for acne and the Kleresca® treatment for skin
rejuvenation combines a topical photo converter in conjunction with a multi-LED
light to create hyper-pulsed multi-wavelength fluorescent light, resulting in
photobiomodulation within the skin. It is based on Klox's patented BioPhotonic
technology platform in dermatology and is currently offered exclusively in
professional clinics.
"We have now successfully introduced the BioPhotonic technology under the
Kleresca® brand in seven countries and have seen a strong interest from the
market. We now want to further expand the offering and its geographical
footprint", said Dr. Patrice Baudry, LEO Pharma's Senior Vice President Global
Strategy and Portfolio Management. "Creating a standalone company with the
backing of Klox and LEO Pharma will allow for greater strategic expansion and
accelerate growth", Baudry continued.
Mr. Mariano Rodriguez, Chief Operating Officer and Chief Financial Officer of
Klox Technologies stated, "This pivotal next step in Klox's collaboration with
LEO Pharma will bring our BioPhotonic technology in dermatology to new heights.
We have made great progress throughout our initial partnership, and establishing
a separate company was the natural next step. We are delighted to continue our
collaboration with LEO Pharma through this new venture and look forward to
accelerating market expansion."
The new venture will be an independently managed company, led by Mr. Mikkel
Schoedt, who previously oversaw the Kleresca® Business Unit at LEO Pharma. To
ensure a smooth transition and to continue delivering quality service to its
customers, the Kleresca® team at LEO Pharma will transfer to the new company,
and LEO Pharma will for the time being, continue to be responsible for
production and support. Further details of the agreement were not disclosed.
About Klox Technologies Inc.
Klox is a specialty pharmaceutical company focused on developing and
commercializing products based on its proprietary BioPhotonic technology
platform to address skin and soft tissue disorders. Klox is advancing its
programs as part of its multiple franchises focusing on indications across
Dermatology, Wound Care, and Oral Health. For more information please
visit www.kloxtechnologies.com
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. By offering care solutions to
patients in more than 100 countries globally, LEO Pharma supports people in
managing their skin conditions. Founded in 1908 and owned by the LEO Foundation,
the healthcare company has devoted decades of research and development to
delivering products and solutions to people with skin conditions. LEO Pharma is
headquartered in Denmark and employs around 5,000 people worldwide.
For more information, visit www.leo-pharma.com and www.kleresca.com
Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal
Follow us on Twitter: www.twitter.com/leohealthyskin
Visit us at LinkedIn: www.linkedin.com/company/leo-pharma
Contact
Klox Technologies Inc.
Carlo Bellini
ir(at)kloxtechnologies.com
+1 (450) 232-2230
LEO Pharma A/S
Henrik Heskjaer Kyndlev
Henrik.kyndlev(at)leo-pharma.com
(+45) 3140 6180
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: KLOX Technologies Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.03.2017 - 16:52 Uhr
Sprache: Deutsch
News-ID 528412
Anzahl Zeichen: 4486
contact information:
Town:
Laval
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Klox Technologies and LEO Pharma set up company for BioPhotonic in dermatology"
steht unter der journalistisch-redaktionellen Verantwortung von
KLOX Technologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
